ABSTRACT: TRPV5 is a Ca 2+ -selective channel involved in transcellular Ca 2+ absorption expressed in kidney and in the ruffled border of osteoclasts. Studies in hypercalciuric TRPV5 knockout (TRPV5 −/− ) mice, which display significantly increased vitamin D levels, showed that TRPV5 ablation increases number and size of osteoclasts but impairs osteoclast-mediated bone resorption. The latter is not in line with the observed decreased bone thickness in TRPV5 −/− mice. Bisphosphonates also inhibit osteoclast-mediated bone resorption. The aim of this study was to evaluate the effect of alendronate on the expression of the Ca 2+ transporters in bone, kidney, and duodenum and, importantly, the bone phenotype in TRPV5 −/− mice. Wildtype (TRPV5 +/+ ) and TRPV5
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−/− mice were treated during 10 wk with 2 mg/kg alendronate or vehicle weekly and housed in metabolic cages at the end of treatment. Urine and blood samples were taken for biochemical analysis, and duodenum, kidney, and femur were sampled. Expression of Ca 2+ transporters and osteoclast ruffled border transporters in bone and cultured osteoclasts was determined by QPCR analysis. Femurs were scanned using CT, and resorption pit assays were performed in bone marrow cultures isolated from TRPV5 +/+ and TRPV5 −/− mice. Alendronate treatment enhanced bone thickness in TRPV5 +/+ mice but also normalized the disturbed bone morphometry parameters in TRPV5 −/− mice. Bone TRPV5 expression was specifically enhanced by alendronate, whereas the expression of Ca 2+ transporters in kidney and intestine was not altered. The expression of the osteoclast ruffled border membrane proteins chloride channel 7 (CLC-7) and the vacuolar H + -ATPase did not differ between both genotypes, but alendronate significantly enhanced the expression and PTH levels in TRPV5 −/− mice. The expression of TRPV5, CLC-7, and H + -ATPase in osteoclast cultures was not affected by alendronate. The number of resorption pits was reduced in TRPV5 −/− bone marrow cultures, but the response to vitamin D was similar to that in TRPV5 +/+ cultures. The alendronate-induced upregulation of TRPV5 in bone together with the decreased resorptive capacity of TRPV5 −/− osteoclasts in vitro suggests that TRPV5 has an important role in osteoclast function. However, our data indicate that significant bone resorption still occurs in TRPV5 −/− mice, because alendronate treatment normalized bone thickness in these mice. Thus, TRPV5 −/− mice are able to rescue the resulting defect in osteoclast-mediated bone resorption, possibly mediated by the long-term hypervitaminosis D or other (non)hormonal compensatory mechanisms. entry across the luminal membrane  through the epithelial Ca  2+ channels TRPV5 and TRPV6, respectively. (2) The majority of the body Ca 2+ content is, thereafter, stored in bone, where the balanced processes of bone formation and resorption maintain bone homeostasis. (3) The expression of TRPV5 and TRPV6 in bone was previously shown, but their physiological roles remained elusive. (4) TRPV5 knockout (TRPV5 −/− ) mice displayed a profound renal Ca 2+ wasting and showed a bone phenotype characterized by reduced bone thickness. (5) Interestingly, TRPV5 ablation was recently shown to result in increased numbers and size of osteoclasts, whereas osteoclast bone resorptive capacity in tibial bone marrow cultures from TRPV5 −/− mice was severely decreased. (6) These data suggested that TRPV5 is involved in osteoclast-mediated bone resorption. However, the impaired osteoclast activity seems at variance with the observed bone phenotype in TRPV5 (5, 12) To further study the significance of TRPV5, we showed that, when Ca 2+ entry through TRPV5 in polarized monolayers of rabbit CNT/CCD is blocked with the potent inhibitor ruthenium red, this eliminated PTH-stimulated transepithelial Ca 2+ transport and simultaneously decreased the expression of calbindin-D 28K and the basolateral NCX1, whereas TRPV5 expression remained unaffected. (13) Together, these data underline the importance of TRPV5 as the gatekeeper in renal active Ca 2+ reabsorption and show that the Ca 2+ influx through TRPV5 controls the expression of the downstream Ca 2+ transport proteins. In addition, a significant hypervitaminosis D was present in TRPV5 −/− mice, along with increased intestinal Ca 2+ absorption. Furthermore, the hypervitaminosis D is responsible for the intestinal hyperabsorption of Ca 2+ through upregulation of the intestinal Ca 2+ transport proteins TRPV6 and calbindin-D 9K . (14) Previously, we showed that, in bone, TRPV5 localizes exclusively to the ruffled border of osteoclasts. (6) Furthermore, calbindin-D 9K , calbindin-D 28K , NCX1, and PMCA1b were shown to be present in these bone cells. (6) Together with the near absence of resorption pit formation by TRPV5 −/− osteoclasts, these data suggested that the transcellular Ca 2+ transport machinery, and TRPV5 in particular, is essential for proper osteoclastic bone resorption. (6) The balance of bone formation and resorption can be clinically influenced by the administration of bisphosphonates, which are used in the treatment of malignancyrelated hypercalcemia and osteolytic bone disease, primary and secondary hyperparathyroidism, Paget's disease of bone, and osteoporosis. (15, 16) Because bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption, the action of these compounds in wildtype (TRPV5 +/+ ) and TRPV5 −/− mice, as well as the effects on the expression of TRPV5 and TRPV6, may add to our knowledge of the physiological role(s) of these epithelial Ca 2+ channels in bone homeostasis. (16) Furthermore, the effect of bisphosphonate treatment on renal and duodenal Ca 2+ (re)absorption has not been evaluated in detail.
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The aim of this study was, therefore, to determine the in vivo effect of the bisphosphonate alendronate on Ca 2+ and bone homeostasis. The expression of the Ca 2+ transport proteins in bone, kidney, and intestine was determined by real-time QPCR analysis and/or semiquantitative immunohistochemistry. The action of alendronate on bone morphology in TRPV5 +/+ mice and, importantly, the bone phenotype in TRPV5 −/− mice, was evaluated by CT. +/+ and TRPV5 −/− mice were treated for 10 wk with 2 mg/kg alendronate (3-amino-1-hydroxypropylidene-1,1-bisphosphonate; n ‫ס‬ 9) or vehicle (n ‫ס‬ 9) once weekly by subcutaneous injection. At the end of the treatment period, the animals were housed in metabolic cages enabling ration feeding and collection of 24-h urine samples under mineral oil, preventing evaporation. After termination of the metabolic experiments, blood samples were taken, and the animals were anesthetized and killed by cervical dislocation. Immediately thereafter, duodenum, kidney, and femur were sampled. Kidney cortex was immediately frozen in liquid nitrogen and, in addition, renal tissue was fixated for immunohistochemistry by immersion in 1% (wt/vol) periodate-lysine-paraformaldehyde (PLP) for 2 h and 15% (wt/vol) sucrose in PBS overnight. Subsequently, kidney and duodenum samples were stored at -80°C until further processing. The animal ethics board of the Radboud University Nijmegen approved all animal studies.
MATERIALS AND METHODS

Alendronate
Analytical procedures
Serum and urine Ca 2+ concentrations were determined using a colorimetric assay as described previously. (17) Na + and Li + concentrations were determined flamespectrophotometrically (Eppendorf FCM 6343), (12) and urine pH was measured using an electronic ion analyzer (Hanna Instruments, Szeged, Hungary). In addition, deoxypyridinoline (DPD) was analyzed in urine (Biometra, San Francisco, CA, USA 
Real-time QPCR analysis
Total RNA was extracted from bone, kidney, and duodenum using TriZol Total RNA Isolation Reagent (Gibco BRL, Breda, The Netherlands). Femurs, from which the bone marrow was removed by flushing with PBS, were first homogenized using a Mikro Dismembrator S (Sartorius, Goettingen, Germany). The obtained RNA was subjected to DNase treatment and reverse transcribed. (4) Subsequently, the cDNA was used to measure TRPV5 and TRPV6 mRNA in bone by real-time QPCR as described previously. (18) In addition, the mRNA levels of the vacuolar H + -ATPase and the Cl − channel ClC-7, which are present in the ruffled border membrane of osteoclasts and involved in bone resorption, were determined. (19) (20) (21) (22) Vacuolar H + -ATPase primer sequences were 5Ј-TCAGATCCTA-AGCCGAAGTTGAG-3Ј and 5Ј-GACCAAGGCCAC-CTCTTCAC-3Ј, and 5Ј-TCCACCTGGGATCATGGGC-TCTATGT-3Ј for the probe. In the case of ClC-7, these were 5Ј-CCTGTGGTGGAGGATGTAGGA-3Ј, 5Ј-TCTCCACAAACACCTTATGCTTCA-3Ј, and 5Ј-TCCAAGGCTTGATCCTGCGTTCCC-3Ј, respectively. Furthermore, TRPV5 and calbindin-D 28K mRNA expression in kidney and TRPV6 and calbindin-D 9K mRNA levels in duodenum were determined. (14, 23) The mRNA expression level of the housekeeping gene hypoxanthine-guanine phosphoribosyl transferase (HPRT) was used as an endogenous control, which enabled calculation of specific mRNA expression levels as a ratio of HPRT.
Immunohistochemistry
Staining of kidney sections for TRPV5 and calbindin-D 28K was performed on cryosections of PLP-fixed kidney samples as described previously. (7, 17) For semiquantitative determination of protein abundance, images were made using a Zeiss fluorescence microscope equipped with a digital camera (Nikon DXM1200). Images were analyzed with the Image Pro Plus 4.1 image analysis software (Media Cybernetics, Silver Spring, MD, USA), resulting in quantification of the protein levels as the mean of integrated optical density (IOD).
Bone analysis
To evaluate the effect of alendronate on the bone phenotype in TRPV5 −/− mice and the possible correlation between TRPV5 and TRPV6 expression and bone homeostasis, femurs from control and alendronate-treated TRPV5 +/+ and TRPV5 −/− mice were scanned using the SkyScan 1072 microtomograph (SkyScan, Antwerp, Belgium). Scans were processed and a 3D morphometric analysis of the bone was performed using the 3D-Calculator project free software (http://www.eur.nl/fgg/orthopaedics) followed by additional analyses, using software available on http://www. skyscan.be/next/downloads.html. Measured parameters were expressed according to bone histomorphometry nomenclature. (24) 
Murine bone marrow cultures and resorption pit assay
Murine bone marrow cultures were performed as described previously. (6) In short, different 1,25(OH) 2 D 3 concentrations were applied to bone marrow cultures for 6 days to study the effect of 1,25(OH) 2 D 3 on bone resorption by TRPV5 +/+ and TRPV5 −/− osteoclasts. Thereafter, murine osteoclasts cultured on bovine cortical bone slices were lysed in water for Coomassie brilliant blue staining of resorption pits. Bovine cortical bone slices were sonicated in 10% (vol/vol) ammonia (Merck) for 10 min. After extensive washing, the cells were incubated in filtered potassium aluminum sulfate (Sigma) for 10 min and subsequently stained with filtered Coomassie brilliant blue (Phastgel Blue R; Amersham Pharmacia Biotech) for 5 s. The resorption pits were analyzed with BIOQUANT software (Bioquant, Nashville, TN, USA). In addition, we determined the effect of alendronate on the expression of TRPV5, the chloride channel CLC-7, and the vacuolar H + -ATPase in cultured osteoclasts by real-time QPCR analysis as described above. To this end, alendronate was applied to the osteoclasts for 24 h at a concentration of 10 −5 M, after which RNA was extracted.
Statistical analysis
Data are expressed as means ± SE. Statistical comparisons were analyzed by one-way ANOVA and Fisher's multiple comparison; p < 0.05 was considered statistically significant. All analyses were performed using the StatView Statistical Package software (Power PC version 4.51) on an Apple iMac computer. 
RESULTS
Metabolic studies in alendronate-treated TRPV5
Bone analysis
To evaluate the effect of alendronate on bone morphology in TRPV5 +/+ and TRPV5 −/− mice, femurs were scanned using CT. Detailed 3D morphometric analysis showed
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−/− MICEthat trabecular thickness (Tb.Th), cortical thickness (Ct.Th), cortical volume (Ct.V.), and cortical bone volume fraction (Ct.V/Dp.V) were decreased in TRPV5 −/− mice ( Table 2) . Treatment with alendronate increased the trabecular bone volume fraction (BV/TV), Ct.Th, and Ct.V/ Dp.V in TRPV5 +/+ mice, confirming the therapeutic efficacy of this bone resorption inhibitor. Interestingly, alendronate increased Tb.Th, BV/TV, Ct.Th, Ct.V, and Ct.V/Dp.V. in TRPV5 −/− mice to levels that did not differ from untreated TRPV5 +/+ mice, showing that alendronate was able to normalize the bone morphology parameters in these mice.
mRNA expression of TRPV5 and osteoclast markers in bone and cultured osteoclasts
Bone TRPV5 mRNA levels in femur, as determined by real-time QPCR analysis, were significantly enhanced by alendronate in TRPV5 +/+ mice (Fig. 1A) . In contrast, bone TRPV6 mRNA levels were unaffected by alendronate treatment (Fig. 1B) . TRPV5 gene ablation did not alter the TRPV6 mRNA levels in femur. To further evaluate the effect of alendronate on osteoclasts, bone mRNA expression levels of the vacuolar H + -ATPase and the chloride channel ClC-7 were determined, which both are expressed at the ruffled border of the osteoclast and are involved in the acidification of resorption pits as part of the process of bone resorption. (19, 20) The vacuolar H + -ATPase ( Fig. 2A ) and ClC-7 mRNA expression (Fig. 2B) was not altered by TRPV5 ablation. Furthermore, alendronate treatment did not alter the expression of these osteoclast markers in TRPV5 +/+ mice. In TRPV5 −/− mice, however, alendronate significantly enhanced the bone vacuolar H + -ATPase and ClC-7 mRNA expression levels. To ascertain whether the above-described transcriptional regulation was the result of a direct effect of alendronate on the osteoclast, we determined the expression of these transport proteins in cultured osteoclasts treated with alendronate. In contrast to the alendronate-induced TRPV5 upregulation in bone, TRPV5 mRNA expression in cultured osteoclasts was not altered by alendronate application (Fig. 3A) . Likewise, the expression of the chloride channel CLC-7 ( Fig. 3B ) and the vacuolar H + -ATPase (Fig. 3C ) was unaltered by alendronate.
Renal and duodenal expression of Ca 2+ transporters
Alendronate administration did not change renal TRPV5 mRNA (Fig. 4A) (Fig. 4B ) and protein expression in DCT and CNT (Figs. 5B and 5D ). However, calbindin-D 28K mRNA (Fig. 4B ) and protein abundance (Figs. 5B and 5D) in both genotypes were not affected by alendronate. TRPV5 ablation resulted in a significantly enhanced intestinal mRNA expression of the Ca 2+ transporters TRPV6 (Fig. 6A ) and calbindin-D 9K (Fig. 6B) . In both TRPV5 +/+ and TRPV5 −/− mice, duodenal TRPV6 and calbindin-D 9K mRNA levels were not altered by alendronate treatment.
Murine bone marrow cultures and resorption pit assay
When bone marrow from TRPV5 +/+ and TRPV5 −/− mice was cultured in the presence of FCS only, the number of resorption pits in TRPV5 −/− was lower compared with wildtype cultures (Fig. 7) . 
DISCUSSION
This study showed that treatment with the bone resorption inhibitor alendronate normalizes the reduced bone thickness in TRPV5 −/− mice. This clearly indicated that significant bone resorption still occurs in these mice. In accor- dance, the expression of other ruffled border transporters involved in osteoclast-mediated bone resorption (i.e., the vacuolar H + -ATPase and ClC-7) remained unchanged in TRPV5 −/− mice. Interestingly, alendronate enhanced osteoclast TRPV5 expression, whereas the expression of the Ca 2+ transporters in kidney and intestine was not affected. This indicated that alendronate specifically affects bone, without altering renal or intestinal active Ca 2+ (re)absorption. Taken together, these data suggest that the severely impaired bone resorptive capacity that was shown in tibial bone marrow cultures from TRPV5 −/− mice (6) is rescued in vivo. Because osteoclast numbers are increased in
TRPV5
−/− mice and these osteoclasts retain 1,25(OH) 2 D 3 responsiveness, the rescue mechanism might involve hypervitaminosis D.
Alendronate treatment during 10 wk enhanced bone thickness in TRPV5 +/+ mice, which substantiates the therapeutic efficacy of this compound in mice. In TRPV5 −/− mice, alendronate normalized the significantly diminished bone thickness and volume parameters compared with TRPV5 +/+ mice and reduced urinary excretion of the bone resorption marker DPD. Furthermore, renal Ca 2+ excretion was diminished by alendronate in these mice, which is in line with less Ca 2+ being released from bone because of 
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inhibition of bone resorption. Previous studies showed that, in bone, TRPV5 is exclusively expressed in the osteoclast ruffled border and that osteoclasts from TRPV5 −/− mice are severely impaired in their bone resorptive capacity. (6) This was exemplified by the near-absence of resorption pit formation by osteoclasts derived from bone marrow cultures of these knockout mice. (6) These data suggested that TRPV5 is essential for proper osteoclastic bone resorption. The significant bone-sparing response to alendronate, however, indicated that TRPV5 −/− mice retain significant osteoclast-mediated bone resorptive capacity. This was substantiated by the unaltered expression of the vacuolar H + -ATPase and the chloride channel ClC-7 in bones from TRPV5 −/− mice, which are expressed along with TRPV5 at the ruffled border of the osteoclast and are crucial to osteoclastic bone resorption. (19, 20) Moreover, mutations in these proteins have been shown to result in osteopetrosis, characterized by increased BMD and decreased bone length. (19, 21, 22, 25) Osteoclasts from ClC-7-deficient mice failed to form resorption pits, whereas osteoclast numbers were increased, features that resemble osteoclast abnormalities in TRPV5 −/− mice. (6, 21, (25) (26) (27) Thus, the severe malfunction of TRPV5 −/− osteoclasts would, theoretically, be expected to lead to the clinical syndrome of osteopetrosis instead of the observed reduced bone thickness in TRPV5 −/− mice. (6) Altogether, these data suggest that in vivo compensatory mechanisms are involved which rescue the impaired resorptive capacity of TRPV5-lacking osteoclasts.
In addition to TRPV5, TRPV6 is also expressed by osteoclasts, suggesting that TRPV6 could compensate for the absence of TRPV5 in TRPV5 −/− mice. (4, 6) However, the expression of TRPV6 in bone was unaltered in TRPV5 −/− mice and not affected by alendronate treatment. Importantly, TRPV5 −/− mice showed significant hypervitaminosis D, which was previously shown to counteract the renal Ca ), in addition to TRPV5 ablation, 1,25(OH) 2 D 3 biosynthesis is impaired. (14) The compensatory Ca 2+ hyperabsorption observed in TRPV5 −/− mice was absent in TRPV5 −/− /1␣-OHase −/− mice. (14) Importantly, the latter mice showed a distinct bone phenotype including reduced bone length, along with severe hypocalcemia and hyperparathyroidism. Whereas physiological doses of 1,25(OH) 2 D 3 inhibit PTH-induced bone resorption, 1,25(OH) 2 D 3 has been suggested to stimulate bone resorption by enhancing osteoclast formation when present at supraphysiological levels. (28, 29) Indeed, both the number of mature osteoclasts and osteoclast precursors in bone marrow of TRPV5 −/− mice were increased, indicating an accelerated osteoclast differentiation pathway in the presence of hypervitaminosis D in these mice. (6) Taken together, these data suggest that the increased 1,25(OH) 2 
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−/− MICEand have previously been shown to paradoxically increase their quantity. (16, (30) (31) (32) (33) (34) (35) This effect was hypothesized to reflect a compensatory feedback mechanism caused by the reduced release of Ca 2+ from bone. (16, 36) The upregulation of CLC-7 and H + -ATPase, transporters known to be involved in resorption pit acidification, observed in our study coincided with a significant rise in serum PTH levels in TRPV5 −/− mice. Because the stimulatory effect of PTH on osteoclast acidification as well as H + -ATPase and ClC-7 has been previously shown, (16, 34, (37) (38) (39) (40) (41) the increased PTH levels are likely responsible.
Whereas significantly increasing PTH levels, alendronate treatment decreased the elevated serum 1,25(OH) 2 D 3 levels in TRPV5 −/− mice. Although intriguing, these hormonal changes are not readily explained. In addition, because the hypervitaminosis D maintains the compensatory Ca 2+ hyperabsorption in TRPV5 −/− mice, alendronate treatment would be expected to result in downregulation of the intestinal Ca 2+ transporters. However, the duodenal expression of these transporters remained unchanged. Tentatively, the high serum PTH or any of its downstream effects is involved in maintaining the Ca 2+ hyperabsorption. Whereas the stimulatory effect of PTH on Ca 2+ transporter expression and Ca 2+ reabsorption has been shown in kidney and PTH receptors are present in intestinal cells, the stimulatory effect on intestinal Ca 2+ absorption is debated. (42) (43) (44) (45) These data indicate that the response to alendronate treatment is different and more exaggerated in TRPV5 −/− mice compared with TRPV5 +/+ mice. It is therefore likely that alendronate-mediated inhibition of bone resorption seriously challenges the fragile Ca 2+ balance in these mice, necessitating at least the prolonged induction of PTH secretion to ultimately maintain normocalcemia. However, the exact mechanism explaining the adapted hormone status in TRPV5 −/− mice remains to be elucidated and warrants further study.
Taken together, our data suggest that the impaired bone resorption by TRPV5 −/− osteoclasts determined in vitro is rescued to a substantial degree in TRPV5 −/− mice in vivo. Possibly, the hypervitaminosis D, in addition to causing Ca 2+ hyperabsorption in intestine, is also involved in the compensatory mechanism rescuing bone resorptive capacity. The apparent interruption of this rescue mechanism by alendronate treatment, whereas increasing bone thickness, seems to critically jeopardize Ca 2+ homeostasis, leading to several compensatory effects including increased PTH secretion. However, these data do not yet explain the bone phenotype in TRPV5 −/− mice. (5, 14) In the presence of an intrinsic defect of bone resorption, reduced bone formation is likely involved. Because bone formation and resorption were shown to be closely related processes, which show a considerable amount of cross-talk, an altered bone formation-resorption coupling might contribute to the reduced bone thickness. (46) (47) (48) (49) In addition, the primary renal Ca 2+ wasting causes a negative Ca 2+ balance, and therefore, less Ca 2+ may be available for bone formation. (5) Of note, 1,25(OH) 2 D 3 treatment of murine osteoblasts was previously shown to inhibit the development of a mature osteoblast phenotype and matrix mineralization. (50) Further studies are needed to unravel the exact relationship between TRPV5 ablation, osteoclast and osteoblast function, serum 1,25(OH) 2 D 3 and PTH levels, and the reduced bone thickness in TRPV5 −/− mice. 
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